HROW vs. HALO
Compare and contrast key facts about Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HROW or HALO.
Key characteristics
| HROW | HALO | |
|---|---|---|
| YTD Return | 403.75% | 40.07% |
| 1Y Return | 291.81% | 47.24% |
| 3Y Return (Ann) | 80.15% | 10.08% |
| 5Y Return (Ann) | 61.72% | 27.93% |
| 10Y Return (Ann) | 20.40% | 18.98% |
| Sharpe Ratio | 3.31 | 1.19 |
| Sortino Ratio | 3.72 | 1.82 |
| Omega Ratio | 1.60 | 1.24 |
| Calmar Ratio | 3.18 | 1.02 |
| Martin Ratio | 15.31 | 5.17 |
| Ulcer Index | 19.55% | 8.62% |
| Daily Std Dev | 90.47% | 37.66% |
| Max Drawdown | -99.46% | -74.26% |
| Current Drawdown | -59.12% | -19.64% |
Fundamentals
| HROW | HALO | |
|---|---|---|
| Market Cap | $2.00B | $6.62B |
| EPS | -$0.95 | $2.58 |
| Total Revenue (TTM) | $119.88M | $657.27M |
| Gross Profit (TTM) | $85.49M | $501.51M |
| EBITDA (TTM) | -$630.00K | $375.07M |
Correlation
The correlation between HROW and HALO is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
HROW vs. HALO - Performance Comparison
In the year-to-date period, HROW achieves a 403.75% return, which is significantly higher than HALO's 40.07% return. Over the past 10 years, HROW has outperformed HALO with an annualized return of 20.40%, while HALO has yielded a comparatively lower 18.98% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HROW vs. HALO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HROW vs. HALO - Dividend Comparison
Neither HROW nor HALO has paid dividends to shareholders.
Drawdowns
HROW vs. HALO - Drawdown Comparison
The maximum HROW drawdown since its inception was -99.46%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HROW and HALO. For additional features, visit the drawdowns tool.
Volatility
HROW vs. HALO - Volatility Comparison
The current volatility for Harrow Health, Inc. (HROW) is 12.09%, while Halozyme Therapeutics, Inc. (HALO) has a volatility of 14.36%. This indicates that HROW experiences smaller price fluctuations and is considered to be less risky than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
HROW vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Harrow Health, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities